NMX RESEARCH AND SOLUTIONS INC.
Discovering novel drug seeds
PUBLICATIONS
NMX stays on the cutting edge of early-stage drug discovery research by constantly expanding and redefining what can be achieved by our biochemical and biophysical tools of choice.
This section features a selection of recently published developments.
Probing the free-state solution behavior of drugs and their tendencies to self-associate into nano-entities.
LaPlante, S.R.; Roux, V.; Shahout, F.; Laplante, G.; Woo, S.; Ayotte, Y.; Denk, M.; Larda, S.T.
Nature Protocols (2021).
Fragment-Based Phenotypic Lead Discovery To Identify New Drug Seeds That Target Infectious Diseases
Yann Ayotte, Eve Bernet, François Bilodeau, Mena Cimino, Dominic Gagnon, Marthe Lebughe,
Maxime Mistretta, Paul Ogadinma, Sarah-Lisa Ouali, Aïssatou Aïcha Sow, Laurent Chatel-Chaix,
Albert Descoteaux, Giulia Manina, Dave Richard, Frédéric Veyrier, and Steven R. LaPlante
ACS Chem. Biol. (2021)
NMR-based Approaches to the Study of GPCRs and GPCR-ligand Interactions.
Pandey, A.; Larda, S.T.; LaPlante, S.R.; Prosser, R.S.
GPCRs Structure, Function, and Drug Discovery (2020): 65-80.
Exposing Small-molecule Nano-entities By An NMR Relaxation Assay.
Ayotte,Y.; Marando,V.M.; Vaillancourt,L.; Bouchard,P.; Heffron,G.; Coote,P.W.; Larda,S.T.; LaPlante,S.R.
J. Med. Chem. (2019), 62; 17: 7885-7896.
Fragment-Based Phenotypic Lead Discovery: Cell-Based Assay to Target Leishmaniasis.
Ayotte Y, Bilodeau F, Descoteaux A, LaPlante SR.
ChemMedChem. (2018) 18;13(14):1377-1386.
NMR strategies to support medicinal chemistry workflows for primary structure determination.
Oguadinma, P.; Bilodeau, F.; LaPlante, S.R.
Bioorganic & Medicinal Chemistry Letters, (2017) 27: 242-247.
Resurgence of Phenotypic Screening for Discovering Drug Leads.
Ayotte, Y & LaPlante, S.R.
EC Microbiology 7.3, (2017): 80-82.
The Rise of Academia-Pharma Partnerships for Discovering New Chemical Matter for Future Drugs.
LaPlante, S; Bilodeau, F.
EC Microbiology 4.5 (2016): 756-758.